 |
 |
 |
| |
Disease Progression Among Commercially Insured Patients Infected With Hepatitis Delta Virus in the United States
|
| |
| |
AASLD 2025 Nov 7-11 Wash DC
Robert G Gish1,2, Robert J Wong3, Chong Kim4, Gary Leung5, Ira M Jacobson6, Joseph K Lim7, Marvin Rock4
1Robert G. Gish Consultants, LLC, San Diego, CA, USA; 2Hepatitis B Foundation, Doylestown, PA, USA; 3Stanford University School of Medicine, Stanford, CA, USA; 4HEOR-Global Value & Access, Gilead Sciences, Inc., Foster City, CA, USA; 5RWE-Epidemiology, Gilead Sciences, Inc., Foster City, CA, USA; 6NYU Grossman School of Medicine, New York, NY, USA; 7Yale University School of Medicine, New Haven, CT, USA








|
| |
|
 |
 |
|
|